AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026 INBX update: CTOS presentations ahead; ozekibart remains under FDA review Headline · Source: company release
NASDAQ: $INBXBiotech · OncologyRegulatory, hepatic-safety and financing risk

INBX Stock Hub: Inhibrx News, Ozekibart and Ordastobart

Inhibrx has an accepted ozekibart BLA with an April 14, 2027 PDUFA date. Ordastobart showed a response signal in HexAgon-HN, alongside substantial treatment-related toxicity. Latest published accounts are Q2 2026: $133.344M June cash; the later corporate presentation reported $219.5M on August 6. Neither drug is approved. Q2 2026 Form 10-Q · August 13 Corporate presentation furnished September 28, 2026 FDA BLA acceptance and PDUFA announcement · June 15, 2026 HexAgon primary-analysis presentation · September 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: June 30, 2026Currency: USD
Research Library · Biotech
Inhibrx: Ozekibart, Ordastobart and the Financing Path
An accepted BLA, randomized oncology data and debt-funded development · November 12, 2026
Get the report (PDF)
Next catalyst · Announced scientific presentation
November 19, 2026 · CTOS Ewing sarcoma poster

The Seoul poster session is scheduled for 17:30–18:30 KST, equivalent to November 19 at 03:30–04:30 in New York. It concerns ozekibart with irinotecan and temozolomide. The ChonDRAgon oral session follows on November 20 at 11:00–12:30 KST, equivalent to November 19 at 21:00–22:30 New York. Scientific conference schedule · October 13, 2026

ESMO on October 25, MSTS on October 29 and BCOG on November 5–6 are past events. The next fixed regulatory date is the April 14, 2027 PDUFA goal; approval is not assured. Scientific conference schedule · October 13, 2026 BCOG colorectal abstract · November 5–6, 2026 FDA BLA acceptance and PDUFA announcement · June 15, 2026
INBX daily price chart
Daily chart · Finviz (affiliate link on click). Explore INBX on JC Just Charts.

INBX stock data: financial position and capital

REFERENCE CLOSE
$90.59
November 11 regular session
COMMON-STOCK VALUE
$1.333B
Calculated using August 7 common shares
LATEST REPORTED CASH
$133.344M
June 30 balance sheet · Q2 accounts
LATER CASH DISCLOSURE
$219.5M
Corporate presentation · August 6
Q2 NET LOSS
$36.650M
Three months ended June 30
OPERATING CASH USED
$67.943M
Six months ended June 30
COMMON SHARES
14.718M
August 7 · excludes 991,849 pre-funded
OZEKIBART PDUFA
April 14, 2027
FDA target date · approval not assured

The July Oxford amendment funded another $100M after the June balance-sheet date. The up-to-$500M facility comprises $275M nominal principal funded across tranches and up to $225M at lenders’ sole discretion; it is not $500M of cash. The August 6 cash figure already follows the July funding. Q2 2026 Form 10-Q · August 13 Corporate presentation furnished September 28, 2026

INBX stock: a PDUFA date with significant safety and financing risks

Ozekibart had one treatment-related hepatic death early in ChonDRAgon before mitigation measures. HexAgon’s safety population recorded grade ≥3 related adverse events in 15/31 combination patients versus 4/34 controls, and treatment discontinuation in 11/31 versus 5/34. ChonDRAgon topline results · October 23, 2025 HexAgon primary-analysis presentation · September 2026

▲ The constructive case

Ozekibart met the randomized ChonDRAgon PFS endpoint and is under FDA review. Ordastobart produced a higher confirmed response rate than pembrolizumab alone in the Phase 2 HexAgon analysis, particularly in the small HPV-positive subgroup. Additional follow-up and expansion cohorts can test durability and reproducibility. FDA BLA acceptance and PDUFA announcement · June 15, 2026 HexAgon-HN primary results · September 8, 2026

▼ The cautious case

BLA acceptance leaves clinical, hepatic-safety, manufacturing and labeling questions for review. The ordastobart subgroup is small and toxicity is material. Inhibrx remains precommercial, with recurring losses, debt covenants, future financing needs and potential dilution. Q2 2026 Form 10-Q · August 13 HexAgon primary-analysis presentation · September 2026

Latest INBX news

Nov 12, 2026

INBX update: CTOS presentations ahead; ozekibart remains under FDA review

As of November 12, Inhibrx's October 13 conference announcement lists a CTOS ozekibart poster on November 19 and a ChonDRAgon oral session on November 20 in Seoul. The oral session is November 19 at 21:00 in New York. FDA accepted the ozekibart BLA in June and set an April 14, 2027 PDUFA date; acceptance is not approval. The latest published financial statements cover June 30, with $133.344M cash and equivalents. The later $219.5M figure in the corporate presentation is dated August 6 and already includes the July debt draw.

Company conference announcement · October 13 · PR Newswire · Company BLA announcement · June 15 · SEC · Q2 Form 10-Q · August 13 · SEC · Corporate presentation · cash as of August 6

INBX stock catalysts: CTOS, ozekibart review and ordastobart expansion

CTOS follows earlier topline results; the scheduled ChonDRAgon session concerns subgroup analysis and updated PFS. Registry completion dates are trial-operational estimates, not promised public readout dates. Scientific conference schedule · October 13, 2026 NCT04950075 · trial registry NCT06295731 · trial registry

Ozekibart: ChonDRAgon and additional combination cohorts

In 206 randomized patients, ChonDRAgon reported median PFS of 5.52 versus 2.66 months, stratified HR 0.479 (95% CI 0.33–0.68), P<0.0001. The accepted BLA concerns conventional chondrosarcoma, not CRC or Ewing sarcoma. ChonDRAgon topline results · October 23, 2025 FDA BLA acceptance and PDUFA announcement · June 15, 2026

The BCOG abstract used an April 10 cutoff: 50 treated CRC patients, 45 evaluable, 20% ORR and 86.7% disease control. It also reported two patients with ozekibart-related grade ≥3 hepatic adverse events. These uncontrolled combination results do not isolate the drug’s contribution. BCOG colorectal abstract · November 5–6, 2026

Ordastobart and HexAgon-HN: response versus tolerability

At the August 19 cutoff, 63 efficacy-evaluable patients had cORR of 48.3% (29 combination patients) versus 26.5% (34 controls). HPV-positive subgroup results were 80.0% in ten versus 33.3% in nine; those small denominators limit precision. HexAgon-HN primary results · September 8, 2026

The safety denominators were 31 and 34. Grade ≥3 related adverse events affected 48.4% versus 11.8%, and discontinuation 35.5% versus 14.7%. The planned expansion adds approximately 50 HPV-positive OPSCC patients with CPS ≥1, broader than the original CPS ≥20 criterion. Accelerated approval remains a development ambition. HexAgon-HN primary results · September 8, 2026 HexAgon primary-analysis presentation · September 2026

Merlintrader Health Score · INBX

3.10out of 5
Financial position2.5

June 30 cash was $133.344M, with $67.943M operating cash used in six months and a $52.977M equity deficit. July added $100M of debt funding; the corporate presentation reported $219.5M cash on August 6. The remaining $225M facility capacity is discretionary. Q2 2026 Form 10-Q · August 13 Corporate presentation furnished September 28, 2026

Catalysts4.0

The accepted ozekibart BLA has an April 14, 2027 PDUFA date. CTOS presentations are announced for November 19–20 in Seoul; ordastobart expansion and perioperative lung data provide later opportunities. Approval and favorable new results remain uncertain. FDA BLA acceptance and PDUFA announcement · June 15, 2026 Scientific conference schedule · October 13, 2026 HexAgon-HN primary results · September 8, 2026

Dilution2.5

June capital included 991,849 pre-funded warrants, approximately 3.437M options and 162,259 Oxford warrants; July added 21,457 warrants. Further financing can dilute common holders, and optional debt capacity also creates a creditor claim. Q2 2026 Form 10-Q · August 13

Trading liquidity3.0

INBX common stock trades on the Nasdaq Global Market, with daily regular-session history. The latest reported common-share count was 14.718M on August 7; concentrated event exposure and a relatively small share base can amplify gaps. Q2 2026 Form 10-Q · August 13

Execution3.5

ChonDRAgon met its randomized PFS endpoint and the BLA was accepted. HexAgon showed a response signal, but grade 3 or worse related adverse events occurred in 15 of 31 combination patients; ozekibart also has material hepatic risk. ChonDRAgon topline results · October 23, 2025 FDA BLA acceptance and PDUFA announcement · June 15, 2026 HexAgon primary-analysis presentation · September 2026

Weighted calculation: 2.5 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.5 × 10% = 3.10 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.

INBX red flags

INBX Stock FAQ: Inhibrx Questions Answered

What is the next INBX stock catalyst for Inhibrx?

As of November 12, 2026, the next announced scientific event is the November 19 CTOS Ewing sarcoma poster, at 17:30–18:30 KST / 03:30–04:30 New York. The ChonDRAgon oral session is November 20 in Seoul, equivalent to November 19 at 21:00–22:30 New York. Scientific conference schedule · October 13, 2026

Is Inhibrx ozekibart FDA-approved, and what is the INBX PDUFA date?

As of November 12, 2026, ozekibart is not FDA-approved; its BLA was accepted for filing with an April 14, 2027 PDUFA goal. The application concerns unresectable or metastatic conventional chondrosarcoma. Acceptance starts substantive review and does not guarantee approval. FDA BLA acceptance and PDUFA announcement · June 15, 2026

How much cash does Inhibrx have for INBX development?

At June 30, 2026, Inhibrx reported $133.344M cash and equivalents. A later corporate presentation reported $219.5M on August 6 after July debt funding. The up-to-$500M Oxford facility is not cash on hand: $225M remains subject to lenders’ sole discretion. Q2 2026 Form 10-Q · August 13 Corporate presentation furnished September 28, 2026

What are the main INBX share dilution risks at Inhibrx?

At June 30, 2026, Inhibrx had 991,849 pre-funded warrants, approximately 3.437M options and 162,259 Oxford warrants, besides common stock. July added 21,457 lender warrants. The 14,717,660 August 7 common-share count excludes those securities; future capital raising can create further dilution. Q2 2026 Form 10-Q · August 13

What are the latest Inhibrx earnings for INBX stock?

As of November 12, 2026, Inhibrx had not announced Q3 2026 results. Its latest published quarter was Q2, released August 13: no revenue, a $36.650M net loss and $133.344M June cash. Operating cash use was $67.943M for the first six months. Q2 2026 Form 10-Q · August 13 Q2 financial results · August 13, 2026 Company news releases

What does Inhibrx Biosciences do, and how is INBX linked to Sanofi?

As of November 12, 2026, Inhibrx Biosciences develops engineered multivalent oncology antibodies, principally ozekibart and ordastobart. The standalone company was separated in May 2024; the INBRX-101 business went to the Sanofi-controlled former parent. The current listed company has SEC CIK 2007919. 2025 Form 10-K · March 19, 2026

What did Inhibrx report for INBX ordastobart in HexAgon-HN?

On September 8, 2026, Inhibrx reported cORR of 48.3% versus 26.5% among 29 and 34 evaluable patients. The HPV-positive subgroup had only ten and nine patients. In the separate safety population, grade ≥3 related events occurred in 15/31 combination patients versus 4/34 controls. HexAgon-HN primary results · September 8, 2026 HexAgon primary-analysis presentation · September 2026

What is the main clinical safety risk for INBX ozekibart?

As of November 12, 2026, hepatic toxicity remains a central ozekibart risk. ChonDRAgon had one early treatment-related hepatic death before mitigation measures. The November BCOG abstract, using an April cutoff, also reported two patients with ozekibart-related grade ≥3 hepatic events in the CRC cohort. ChonDRAgon topline results · October 23, 2025 BCOG colorectal abstract · November 5–6, 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $INBX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models